Akebia Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKBA research report →
About the company
Akebia Therapeutics, Inc. , established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials.
- CEO
- John Butler
- IPO
- 2014
- Employees
- 181
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $332.64M
- P/E
- -16.14
- P/S
- 1.43
- P/B
- 12.10
- EV/EBITDA
- -31.68
- Div Yield
- 0.00%
- Gross Margin
- 80.87%
- Op Margin
- 2.28%
- Net Margin
- -8.83%
- ROE
- -62.72%
- ROIC
- 2.63%
- Revenue
- $236.20M · 47.46%
- Net Income
- $-5,345,000 · 92.30%
- EPS
- $-0.02 · 93.70%
- Op Income
- $23.50M
- FCF YoY
- 267.09%
- 52W High
- $4.08
- 52W Low
- $0.82
- 50D MA
- $1.13
- 200D MA
- $1.62
- Beta
- 0.25
- Avg Volume
- 4.76M
Get TickerSpark's AI analysis on AKBA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Ostrowski Erik | sell | 56,019 |
| Jun 17, 26 | Wolf Myles | other | 35,700 |
| Jun 17, 26 | Wolf Myles | other | 53,600 |
| Jun 17, 26 | Smith Cynthia | other | 35,700 |
| Jun 17, 26 | Smith Cynthia | other | 53,600 |
| Jun 17, 26 | ROGERS MICHAEL W | other | 35,700 |
| Jun 17, 26 | ROGERS MICHAEL W | other | 53,600 |
| Jun 17, 26 | FRIESON RON | other | 35,700 |
| Jun 17, 26 | FRIESON RON | other | 53,600 |
| Jun 17, 26 | ZUMWALT LEANNE M | other | 35,700 |
Our AKBA coverage
Recent articles, reports, and earnings notes.
No research on AKBA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AKBA report →Similar companies
Peers in the same neighborhood.